Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Johan F. Vansteenkiste"'
Autor:
Johan F. Vansteenkiste, MD, PhD, Jarushka Naidoo, MB, BCH, MHS, Corinne Faivre-Finn, MD, PhD, Mustafa Özgüroğlu, MD, Augusto Villegas, MD, Davey Daniel, MD, Shuji Murakami, MD, Rina Hui, M.B.B.S., PhD, Ki Hyeong Lee, MD, Byoung Chul Cho, MD, PhD, Kaoru Kubota, MD, PhD, Helen Broadhurst, MSc, Catherine Wadsworth, BVSc, Michael Newton, PharmD, Piruntha Thiyagarajah, MD, Scott J. Antonia, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100638- (2024)
Introduction: In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p = 0.00251) in patients with unresectable stage III NSCLC and no progression a
Externí odkaz:
https://doaj.org/article/86197b668ce247a6aed1dbb164a76e9d
Autor:
Fernando Ulloa-Montoya, Jamila Louahed, Vincent G. Brichard, Bart Spiessens, Channa Debruyne, Patrick Therasse, Fawn Wang, Susana Salceda, Hans van Houwelingen, Jelle Goeman, Djordje Atanackovic, Lecia V. Sequist, Johan F. Vansteenkiste, John M. Kirkwood, Helen J. Gogas, Peter Hersey, Brigitte Dreno, Muriel Debois, Andrea Callegaro, Benjamin Dizier
Supplementary material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5528f31009db1e47f0a2c403009ea8f6
https://doi.org/10.1158/1078-0432.22473330.v1
https://doi.org/10.1158/1078-0432.22473330.v1
Autor:
Fernando Ulloa-Montoya, Jamila Louahed, Vincent G. Brichard, Bart Spiessens, Channa Debruyne, Patrick Therasse, Fawn Wang, Susana Salceda, Hans van Houwelingen, Jelle Goeman, Djordje Atanackovic, Lecia V. Sequist, Johan F. Vansteenkiste, John M. Kirkwood, Helen J. Gogas, Peter Hersey, Brigitte Dreno, Muriel Debois, Andrea Callegaro, Benjamin Dizier
Purpose:Immune components of the tumor microenvironment (TME) have been associated with disease outcome. We prospectively evaluated the association of an immune-related gene signature (GS) with clinical outcome in melanoma and non–small cell lung c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ba2c738c013635e68f3f047ad124642
https://doi.org/10.1158/1078-0432.c.6528486
https://doi.org/10.1158/1078-0432.c.6528486
Autor:
David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz-Ares, Johan F. Vansteenkiste, Marina C. Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Özgüroğlu, Ki H. Lee, Terufumi Kato, Maike de Wit, Takayasu Kurata, Martin Reck, Byoung C. Cho, Suresh Senan, Jarushka Naidoo, Helen Mann, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia
Publikováno v:
Spigel, D R, Faivre-Finn, C, Gray, J E, Vicente, D, Planchard, D, Paz-Ares, L, Vansteenkiste, J F, Garassino, M C, Hui, R, Quantin, X, Rimner, A, Wu, Y-L, Özgüroğlu, M, Lee, K H, Kato, T, de Wit, M, Kurata, T, Reck, M, Cho, B C, Senan, S, Naidoo, J, Mann, H, Newton, M, Thiyagarajah, P & Antonia, S J 2022, ' Five-Year Survival Outcomes From the PACIFIC Trial : Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 12, pp. 1301-1311 . https://doi.org/10.1200/JCO.21.01308
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(12), 1301-1311. American Society of Clinical Oncology
Spigel, D R, Faivre-Finn, C, Gray, J E, Vicente, D, Planchard, D, Paz-Ares, L, Vansteenkiste, J F, Garassino, M C, Hui, R, Quantin, X, Rimner, A, Wu, Y-L, Özgüroğlu, M, Lee, K H, Kato, T, Wit, M D, Kurata, T, Reck, M, Cho, B C, Senan, S, Naidoo, J, Mann, H, Newton, M, Thiyagarajah, P & Antonia, S J 2022, ' Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.21.01308
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(12), 1301-1311. American Society of Clinical Oncology
Spigel, D R, Faivre-Finn, C, Gray, J E, Vicente, D, Planchard, D, Paz-Ares, L, Vansteenkiste, J F, Garassino, M C, Hui, R, Quantin, X, Rimner, A, Wu, Y-L, Özgüroğlu, M, Lee, K H, Kato, T, Wit, M D, Kurata, T, Reck, M, Cho, B C, Senan, S, Naidoo, J, Mann, H, Newton, M, Thiyagarajah, P & Antonia, S J 2022, ' Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.21.01308
PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with sig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d7eafbcbb57f61fad4fd50892336d30
https://doi.org/10.1200/jco.21.01308
https://doi.org/10.1200/jco.21.01308
Autor:
Jarushka Naidoo, Johan F. Vansteenkiste, Corinne Faivre-Finn, Mustafa Özgüroğlu, Shuji Murakami, Rina Hui, Xavier Quantin, Helen Broadhurst, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia
Publikováno v:
Naidoo, J, Vansteenkiste, J F, Faivre-Finn, C, Özgüroğlu, M, Murakami, S, Hui, R, Quantin, X, Broadhurst, H, Newton, M, Thiyagarajah, P & Antonia, S J 2022, ' Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC : A post-hoc analysis of the PACIFIC trial ', Lung cancer (Amsterdam, Netherlands), vol. 166, pp. 84-93 . https://doi.org/10.1016/j.lungcan.2022.02.003
INTRODUCTION: Immune-mediated adverse events (imAEs), including all-cause immune-mediated pneumonitis, were reported in approximately 25% of patients in the placebo-controlled, phase III PACIFIC trial of durvalumab monotherapy (for up to 12 months) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89e16dda9596d62cf0df0a74ace62e6
https://research.manchester.ac.uk/en/publications/453b2850-fdfc-4cf7-9328-aac1c743a35f
https://research.manchester.ac.uk/en/publications/453b2850-fdfc-4cf7-9328-aac1c743a35f
Autor:
Jacques De Grève, Jan Van Meerbeeck, Johan F Vansteenkiste, Lore Decoster, Anne-Pascale Meert, Peter Vuylsteke, Christian Focan, Jean-Luc Canon, Yves Humblet, Guy Berchem, Benoit Colinet, Danny Galdermans, Lionel Bosquée, Joanna Vermeij, Alex Dewaele, Caroline Geers, Denis Schallier, Erik Teugels
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0147599 (2016)
INTRODUCTION:Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data available pertain to
Externí odkaz:
https://doaj.org/article/d77d90c2874a41ca9219fe0d09d1012a
Autor:
Pierre Jean Souquet, Sang-We Kim, Johan F. Vansteenkiste, Anna Robeva, Aline Jary, Sabine Glaser, Alejandro Yovine, Juergen Wolf
Publikováno v:
Cancer Research. 82:CT558-CT558
Background: MET dysregulation is a poor prognostic factor in advanced non-small cell lung cancer (NSCLC). MET exon 14 skipping (METex14) mutations occur in ~3% of patients with NSCLC. There is limited evidence of the efficacy of standard therapies, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa0980d0778881232b24747a3a795ff3
https://doi.org/10.1158/1538-7445.am2022-ct558
https://doi.org/10.1158/1538-7445.am2022-ct558
Autor:
Lewis Adams, Dan Elie Adler, Alvar Agusti, Evangelia Akoumianaki, Anthony J. Alberg, Kurt H. Albertine, Barbara D. Alexander, Paul H. Alfille, Devanand Anantham, Douglas A. Arenberg, Najib T. Ayas, Aranya Bagchi, John Randolph Balmes, Niaz Banaei, Christopher F. Barnett, Robert P. Baughman, Margaret R. Becklake, Joshua O. Benditt, Neal L. Benowitz, Nirav R. Bhakta, Anant D. Bhave, Paul D. Blanc, Eugene R. Bleecker, Alfred A. Bove, T. Douglas Bradley, Elisabeth Brambilla, V. Courtney Broaddus, Laurent Brochard, Malcolm V. Brock, Kevin K. Brown, Paul G. Brunetta, Jacques Cadranel, Bartolome Celli, Edward D. Chan, Richard N. Channick, Jean Chastre, Guang-Shing Cheng, Kelly Chin, Kian Fan Chung, Christine Clerici, Thomas V. Colby, Harold R. Collard, Carlyne D. Cool, Jean-François Cordier, Ricardo Luiz Cordioli, Tamera J. Corte, Vincent Cottin, Mark S. Courey, Robert L. Cowie, Kristina Crothers, Gerard F. Curley, Charles L. Daley, J. Lucian Davis, Teresa De Marco, Stanley C. Deresinski, Christophe Deroose, Leland G. Dobbs, Christophe Dooms, Gregory P. Downey, Roland M. du Bois, Megan M. Dulohery, Richard M. Effros, Mark D. Eisner, Brett M. Elicker, Armin Ernst, Joel D. Ernst, John V. Fahy, Peter F. Fedullo, David Feller-Kopman, Brett E. Fenster, Tasha E. Fingerlin, Andrew P. Fontenot, Stephen K. Frankel, Joe G.N. Garcia, G.F. Gebhart, Daniel Lee Gilstrap, Nicolas Girard, Mark T. Gladwin, Robb W. Glenny, Warren M. Gold, Michael B. Gotway, Giacomo Grasselli, James M. Greenberg, David E. Griffith, James F. Gruden, MeiLan King Han, William Henderson, Nicholas S. Hill, Wynton Hoover, Philip C. Hopewell, Jennifer L. Horan-Saullo, Richard L. Horner, Laurence Huang, Gérard Huchon, Yoshikazu Inoue, Michael D. Iseman, James E. Jackson, Claudia V. Jakubzick, Julius P. Janssen, James R. Jett, Kirk Jones, Marc A. Judson, Midori Kato-Maeda, Brian P. Kavanagh, Shaf Keshavjee, Kami Kim, R. John Kimoff, Talmadge E. King, Jeffrey S. Klein, Laura L. Koth, Robert M. Kotloff, Monica Kraft, Elif Küpeli, John G. Laffey, Stephen E. Lapinsky, Stephen C. Lazarus, Frances Eun-Hyung Lee, Jarone Lee, Y.C. Gary Lee, Warren L. Lee, Teofilo L. Lee-Chiong, Catherine Lemière, Richard W. Light, Andrew H. Limper, Robert Loddenkemper, Njira Lugogo, Maurizio Luisetti, Andrew M. Luks, Charles-Edouard Luyt, Roberto F. Machado, Neil R. MacIntyre, William MacNee, David K. Madtes, Lisa A. Maier, Fabien Maldonado, Atul Malhotra, Thomas R. Martin, Nick A. Maskell, Robert J. Mason, Pierre P. Massion, Michael A. Matthay, Richard A. Matthay, Annyce S. Mayer, Stuart B. Mazzone, F. Dennis McCool, Francis Xavier McCormack, Atul C. Mehta, Rosario Menéndez, Adam S. Morgenthau, Alison Morris, Timothy A. Morris, Aaron R. Muncey, John F. Murray, Jeffrey L. Myers, Jay A. Nadel, Catherine Nelson-Piercy, Tom S. Neuman, Joshua D. Nosanchuk, Thomas G. O'Riordan, Victor Enrique Ortega, Prasad M. Panse, William Pao, Peter A. Paré, David R. Park, Nicholas J. Pastis, Nicolò Patroniti, Karen C. Patterson, Antonio Pesenti, Allan Pickens, Benjamin A. Pinsky, Steven D. Pletcher, Frank L. Powell, Loretta G. Que, Elizabeth F. Redente, David W.H. Riches, Bruce W.S. Robinson, Roberto Rodriguez-Roisin, Cecile S. Rose, John M. Routes, Steven M. Rowe, Clodagh M. Ryan, Jay H. Ryu, Jonathan M. Samet, Christian E. Sandrock, Robert B. Schoene, David A. Schwartz, Richard M. Schwartzstein, Marvin I. Schwarz, Moisés Selman, Lecia V. Sequist, John M. Shannon, Claire L. Shovlin, Gerard A. Silvestri, Philip L. Simonian, Jonathan P. Singer, Arthur S. Slutsky, Gerald C. Smaldone, George M. Solomon, Eric J. Sorscher, Erik R. Swenson, Nichole T. Tanner, Herbert B. Tanowitz, Antoni Torres, Bruce C. Trapnell, William David Travis, John J. Treanor, George E. Tzelepis, Olivier Vandenplas, Johan F. Vansteenkiste, Thomas K. Varghese, Jørgen Vestbo, Peter D. Wagner, Momen M. Wahidi, W. Dean Wallace, Louis M. Weiss, Scott T. Weiss, Athol U. Wells, John B. West, Douglas B. White, Jeanine P. Wiener-Kronish, Kathryn A. Wikenheiser-Brokamp, Prescott G. Woodruff, Richard G. Wunderink, D. Dante Yeh, Rachel L. Zemans, Leslie Zimmerman, Richard L. Zuwallack
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b2a2c60906532fbaac7fc1e56e2e280
https://doi.org/10.1016/b978-1-4557-3383-5.00138-x
https://doi.org/10.1016/b978-1-4557-3383-5.00138-x
Autor:
Hisao, Asamura, Kari, Chansky, John, Crowley, Peter, Goldstraw, Valerie W, Rusch, Johan F, Vansteenkiste, Hirokazu, Watanabe, Yi-Long, Wu, Marcin, Zielinski, David, Ball, Ramon, Rami-Porta, K, Yokoi
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 10(12)
Nodal status is considered to be one of the most reliable indicators of the prognosis in patients with lung cancer and thus is indispensable in determining the optimal therapeutic options. We sought to determine whether the current nodal (N) descript
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::52a2636bfa446e1f2118ff7edc4bd21f
https://pubmed.ncbi.nlm.nih.gov/26709477
https://pubmed.ncbi.nlm.nih.gov/26709477
Autor:
Johan F. Vansteenkiste, Kay E. Smith, Sevilay Altintas, Tony W. Mossman, Bernd Gaede, An Vandebroek, Laurent Bastit, Tamás Pintér, Tamas S. Suto
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(10)
Purpose The concomitant use of intravenous (IV) iron as a supplement to erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia is controversial. This study was designed to evaluate the efficacy and safety of darbepoetin alfa g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d5d856c5c91266c009584690d837086
https://pubmed.ncbi.nlm.nih.gov/18936789
https://pubmed.ncbi.nlm.nih.gov/18936789